Literature DB >> 26085957

Comparisons of VLP-Based ELISA, Neutralization Assays with Native HPV, and Neutralization Assays with PsV in Detecting HPV Antibody Responses in HIV-Infected Women.

Ping Du1, Sarah Brendle2, Janice Milici3, Fabian Camacho4, John Zurlo5, Neil Christensen2, Craig Meyers3.   

Abstract

OBJECTIVE: Human papillomavirus (HPV)-associated cancers are important public health problems in HIV-infected people. Assays based on HPV virus-like particles (VLP) and pseudoviruses (PsV) are commonly used to examine HPV antibody responses in HIV-infected people, but neutralization assays with native HPV have not been utilized and a comparison of these three assays is lacking. We evaluated the agreement of assays using VLP, native HPV and PsV in detecting HPV16 and 18 antibodies in HIV-infected women.
METHODS: The VLP-based ELISA (VLP-ELISA) was used to detect antibody responses to HPV16 and 18 and cottontail rabbit papillomavirus (CRPV) VLP antigens. Neutralization assays with native HPV (NA-HPV) and with PsV (NA-PsV) were conducted to examine HPV16 or 18 neutralizing antibodies. Intra class correlation coefficients (ICC) and kappa coefficients were used to assess the agreements of seropositivity between the assays.
RESULTS: The seroprevalence detected by the VLP-ELISA, NA-HPV and NA-PsV in 94 HIV-infected women was 35%, 51% and 27% for HPV16 and 14%, 44% and 21% for HPV18. Cross-reactivity between HPV16 and HPV18 was 0.35, 0.04 and 0.33 (kappa coefficients) for the VLP-ELISA, NA-HPV and NA-PsV. The agreements of seropositivity between the three assays were low. Six women who were HPV16 DNA positive were seropositive by the NA-HPV but only two were HPV16 seropositive by the VLP-ELISA or NA-PsV. One HPV18 DNA positive woman was seropositive by all three assays. Repeated tests indicated excellent reproducibility of the NA-HPV.
CONCLUSION: HPV serology results vary across different assays. The NA-HPV appears to be a sensitive and reliable approach in detecting natural HPV antibodies in HIV-infected women. The NA-HPV can be applied in both HPV natural history studies and vaccine studies in HIV-infected people.

Entities:  

Keywords:  ELISA; HIV-infected women; Human papillomavirus; Neutralization assay; Pseudoviruses; Virus-like particles

Year:  2015        PMID: 26085957      PMCID: PMC4467835          DOI: 10.4172/2155-6113.1000433

Source DB:  PubMed          Journal:  J AIDS Clin Res


  37 in total

Review 1.  Human papillomavirus, cancer and vaccination.

Authors:  Isabelle Heard
Journal:  Curr Opin HIV AIDS       Date:  2011-07       Impact factor: 4.283

2.  Propagation, infection, and neutralization of authentic HPV16 virus.

Authors:  Margaret E McLaughlin-Drubin; Neil D Christensen; Craig Meyers
Journal:  Virology       Date:  2004-05-01       Impact factor: 3.616

3.  Maturation of papillomavirus capsids.

Authors:  Christopher B Buck; Cynthia D Thompson; Yuk-Ying S Pang; Douglas R Lowy; John T Schiller
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

4.  A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study.

Authors:  Nicolas Wentzensen; Ana Cecilia Rodriguez; Raphael Viscidi; Rolando Herrero; Allan Hildesheim; Arpita Ghosh; Jorge Morales; Sholom Wacholder; Diego Guillen; Mario Alfaro; Mahboobeh Safaeian; Robert D Burk; Mark Schiffman
Journal:  J Infect Dis       Date:  2011-07-01       Impact factor: 5.226

5.  Specific serum IgG, IgM and IgA antibodies to human papillomavirus types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive women.

Authors:  A Petter; K Heim; M Guger; A Ciresa-Kö Nig; N Christensen; M Sarcletti; U Wieland; H Pfister; R Zangerle; R Höpfl
Journal:  J Gen Virol       Date:  2000-03       Impact factor: 3.891

6.  Heparin-based ELISA reduces background reactivity in virus-like particle-based papillomavirus serology.

Authors:  Xiaohong Wang; Martin Sapp; Neil D Christensen; Joakim Dillner
Journal:  J Gen Virol       Date:  2005-01       Impact factor: 3.891

7.  Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial.

Authors:  Mel Krajden; Darrel Cook; Amanda Yu; Ron Chow; Wendy Mei; Shelly McNeil; Deborah Money; Marc Dionne; Karuna P Karunakaran; Joel M Palefsky; Simon Dobson; Gina Ogilvie; Martin Petric
Journal:  Clin Vaccine Immunol       Date:  2011-01-19

8.  Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.

Authors:  R Kirnbauer; F Booy; N Cheng; D R Lowy; J T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

9.  Kinetics of in vitro adsorption and entry of papillomavirus virions.

Authors:  Timothy D Culp; Neil D Christensen
Journal:  Virology       Date:  2004-02-05       Impact factor: 3.616

10.  Cross-neutralization potential of native human papillomavirus N-terminal L2 epitopes.

Authors:  Michael J Conway; Linda Cruz; Samina Alam; Neil David Christensen; Craig Meyers
Journal:  PLoS One       Date:  2011-02-08       Impact factor: 3.240

View more
  5 in total

1.  Development of a pseudovirus-based assay for measuring neutralizing antibodies against Coxsackievirus A10.

Authors:  Kelei Li; Fangyu Dong; Bopei Cui; Lisha Cui; Pei Liu; Chao Ma; Haifa Zheng; Xing Wu; Zhenglun Liang
Journal:  Hum Vaccin Immunother       Date:  2019-12-18       Impact factor: 3.452

2.  Passive Immunization with a Single Monoclonal Neutralizing Antibody Protects against Cutaneous and Mucosal Mouse Papillomavirus Infections.

Authors:  Sarah A Brendle; Jingwei Li; Nancy M Cladel; Karla K Balogh; Jennifer Booth; Debra A Shearer; Vonn Walter; Song Lu; Neil D Christensen; Danielle Covington; Jake DeBroff; Janice Milici; Yusheng Zhu; Raphael Viscidi; Jiafen Hu
Journal:  J Virol       Date:  2022-08-03       Impact factor: 6.549

3.  SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with nonsevere disease.

Authors:  Thomas J Gniadek; Joshua M Thiede; William E Matchett; Abigail R Gress; Kathryn A Pape; Jessica K Fiege; Marc K Jenkins; Vineet D Menachery; Ryan A Langlois; Tyler D Bold
Journal:  Transfusion       Date:  2020-10-02       Impact factor: 3.157

4.  Correlation between cervical HPV DNA detection and HPV16 seroreactivity measured with L1-only and L1+L2 viral capsid antigens.

Authors:  Andrea Trevisan; João M G Candeias; Patrícia Thomann; Luisa L Villa; Eduardo L Franco; Helen Trottier
Journal:  J Med Microbiol       Date:  2020-07       Impact factor: 2.472

5.  Antibodies to human papillomavirus types 6, 11, 16 and 18: Vertical transmission and clearance in children up to two years of age.

Authors:  Monica Zahreddine; Marie-Hélène Mayrand; Christian Therrien; Andrea Trevisan; Carole Dagenais; Patricia Monnier; Louise Laporte; Joseph Niyibizi; Catherine Deshaies; Ana Maria Carceller; William Fraser; Paul Brassard; Jacques Lacroix; Marie-Josée Bédard; Isabelle Girard; François Audibert; François Coutlée; Helen Trottier
Journal:  EClinicalMedicine       Date:  2020-04-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.